Vancouver, Dec. 28, 2023 (GLOBE NEWSWIRE) -- The global atopic dermatitis drugs market size was USD 6.10 Billion in 2022 and is expected to register a rapid revenue CAGR of 15.2% during the forecast period. The global atopic dermatitis drugs market is experiencing substantial growth, emerging as the most prevalent chronic inflammatory skin condition. According to the National Library of Medicine of NCBI, atopic dermatitis affects 10% to 30% of children and 2% to 10% of adults in developed countries. The market is witnessing a boost in revenue attributed to regulatory approvals, robust Research & Development (R&D) investments, and a surge in biologics for atopic dermatitis management.
In a notable development, the U.S. Food and Drug Administration (FDA) granted approval to Arcutis Biotherapeutics in October 2023 for the supplemental New Drug Application (sNDA) of Zoryve (roflumilast) cream, expanding treatment options for plaque psoriasis in children aged 6 to 11 years.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2588
The National Eczema Association (NEA) has played a pivotal role by announcing significant research grants for 2023, amounting to USD 100,000. This highlights the industry's commitment to advancing the understanding and treatment of atopic dermatitis. The discovery of over 70 new compounds in development underscores the industry's dedication to addressing the needs of atopic dermatitis patients.
However, the market faces challenges due to the high cost of atopic dermatitis treatment in some developing countries. Additionally, adverse effects of certain medications, especially in children and individuals with severe forms of the condition, pose a constraint. Allergic reactions to off-label therapies and product patent expiry further contribute to potential obstacles in market revenue growth.
Product Insights: Biologics Dominate Market Share
The global atopic dermatitis drugs market is segmented into biologics, calcineurin inhibitors, PDE-4 inhibitors, and corticosteroids. Biologics emerged as the largest revenue contributor in 2022, driven by increasing consumer awareness and investments in innovative, highly effective therapies. Calcineurin inhibitors are expected to experience steady revenue growth, fueled by rising organ transplant cases and government initiatives promoting awareness about autoimmune diseases.
Mode of Administration Insights: Injectable Segment Takes the Lead
In terms of administration, the injectable segment is projected to hold a substantial revenue share during the forecast period. This is attributed to increased Research & Development (R&D) focused on pediatric patients, with injectable biologics like tofacitinib and ruxolitinib undergoing clinical trials. The oral segment is expected to register moderate growth, benefiting from recent advancements in understanding disease mechanisms.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @
https://www.emergenresearch.com/request-discount/2588
End-Use Insights: Hospitals Lead, Retail Grows Rapidly
The hospital pharmacies segment is expected to dominate the market, driven by the increasing demand for atopic dermatitis medications and various governmental initiatives strengthening hospital and pharmacy infrastructure. Retail pharmacies are anticipated to register the fastest growth rate, influenced by policies impacting patient access to prescription drugs and the availability of over-the-counter medications.
Regional Insights: North America Tops Market Share
North America accounted for the largest revenue share in 2022, attributed to the rising prevalence of atopic dermatitis, increased awareness, and technological advancements. According to the 2022 National Eczema Association, an estimated 16.5 million U.S. individuals have atopic dermatitis. Europe is expected to witness the fastest revenue growth, driven by lifestyle changes, a growing atopic dermatitis population, and environmental factors. The Asia Pacific market is anticipated to contribute significantly to global revenue, supported by developing healthcare technology, a large patient population, and rising healthcare expenditure.
Scope of Research
| Report Details | Outcome |
| Market Size in 2022 | USD 6.10 Billion |
| CAGR (2023–2032) | 15.2% |
| Revenue Forecast To 2032 | USD 25.20 Billion |
| Base Year For Estimation | 2022 |
| Historical Data | 2019–2021 |
| Forecast Period | 2023–2032 |
| Quantitative Units | Revenue in USD Billion and CAGR in % from 2022 to 2032 |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | Product, mode of administration, end-use, and region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Country Scope | U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Benelux, Russia, Rest of Europe, China, India, Japan, South Korea, ASEAN Countries, Oceania, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, and Rest of Middle East & Africa |
| Key Companies Profiled | Sanofi, Incyte., Pfizer Inc., AbbVie Inc., LEO Pharma, Teva Pharmaceutical Industries Ltd., GALDERMA, Allergan India Private Limited, Bristol-Myers Squibb Company, Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., Valeant Pharmaceuticals International, Inc., Eli Lilly and Company, Astellas Pharma Inc., Anacor Pharmaceutical, Bayer AG, Novartis AG, Asana BioSciences, LLC., Viatris Inc., and Dermavant Sciences, Inc. |
| Customization Scope | 10 hours of free customization and expert consultation |
Direct Order Can Be Placed Through This Link [Exclusive Copy] @
https://www.emergenresearch.com/select-license/2588
Major Companies and Competitive Landscape
The global atopic dermatitis drugs market is fairly fragmented with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective atopic dermatitis drugs solutions. Some major players included in the global atopic dermatitis drugs market report are:
- Sanofi
- Incyte
- Pfizer Inc.
- AbbVie Inc.
- LEO Pharma
- Teva Pharmaceutical Industries Ltd.
- GALDERMA
- Allergan India Private Limited
- Bristol-Myers Squibb Company
- Meda Pharmaceuticals
- Regeneron Pharmaceuticals Inc.
- Valeant Pharmaceuticals International, Inc.
- Eli Lilly and Company
- Astellas Pharma Inc.
- Anacor Pharmaceutical
- Bayer AG
- Novartis AG
- Asana BioSciences, LLC.
- Viatris Inc.
- Dermavant Sciences, Inc.
Strategic Development
- On 13 September 2023, Arcutis Biotherapeutics, submitted a supplemental new drug application to the Food and Drug Administration (FDA) for its roflumilast cream, which is approved for atopic dermatitis in patients aged 6 and older. The cream, also known as Zoryve, treats plaque psoriasis in the U.S.
- On 24 August 2021, AbbVie, The European Commission, a prominent developing region in Atopic Dermatitis market, approved RINVOQ as the first JAK inhibitor in the European Union for treating moderate to severe atopic dermatitis in adults and adolescents. The approval is based on data from a Phase 3 program evaluating RINVOQ monotherapy or with topical corticosteroids, showing rapid improvement in skin clearance and itch reduction.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@
https://www.emergenresearch.com/industry-report/atopic-dermatitis-drugs-market
For the purpose of this report, Emergen Research has segmented the global atopic dermatitis drugs market on the basis of product, mode of administration, end-use, and region:
- Product Outlook (Revenue, USD Billion; 2019-2032)
- Biologics
- Calcineurin Inhibitors
- PDE-4 Inhibitors
- Corticosteroids
- Others
- Mode of Administration Outlook (Revenue, USD Billion; 2019-2032)
- Topical
- Injectable
- Oral
- End-use Outlook (Revenue, USD Billion; 2019-2032)
- Hospital
- Retail
- Online
- Regional Outlook (Revenue, USD Billion; 2019–2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Benelux
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- ASEAN Countries
- Oceania
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- Israel
- Turkey
- South Africa
- Rest of Middle East & Africa
- North America
Curated Reports You Shouldn't Miss: Dive In Now!
Cerebral/Somatic Oximetry Market, By Type (Dual Emitter and Dual Detector, Single Emitter and Dual Detector, and Others), By Patient Type (Pediatrics and Adults), By Application, By End-Use, and By Region Forecast to 2032
Mechanical Ventilator Market, By Product Type (Intensive Care Unit/Critical Care, Transport/Portable/Ambulatory, and Neonatal Care), By Ventilation Mode (Noninvasive and Invasive), By End-Use, By Region Forecast to 2032
Antimicrobial Medical Textiles Market, By Product Type (Polypropylene Powder Coating, PVC Powder Coating, Polypropylene Powder Coating, and Others), By Application, By Active Agent, and By Region Forecast to 2032
Blood Glucose Monitoring System Market, By Product (Self-Monitoring Blood Glucose Systems and Continuous Glucose Monitoring Systems), By Testing Site), By Patient Care, By Application, and By Region Forecast to 2032
Emergency Medical Services (EMS) Products Market, By Type (Life Support and Emergency Resuscitation Systems), By Application, By End-use, and By Region Forecast to 2032
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights
